| 001 | 276077 | ||
| 005 | 20240229154955.0 | ||
| 024 | 7 | _ | |a 10.1055/a-2070-7572 |2 doi |
| 024 | 7 | _ | |a pmid:37172610 |2 pmid |
| 024 | 7 | _ | |a 0300-8630 |2 ISSN |
| 024 | 7 | _ | |a 1439-3824 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2023-00983 |
| 041 | _ | _ | |a German |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Obrecht, Denise |0 0000-0002-3216-8452 |b 0 |
| 245 | _ | _ | |a Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group.[Kinder und Jugendliche mit intrakraniellem Ependymom – Empfehlungen der HIT-MED-Studiengruppe der GPOH zur Erstlinientherapie]. |
| 260 | _ | _ | |a Stuttgart |c 2023 |b Thieme |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1685440437_28112 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Biological subtypes of ependymoma (EPN) have been introduced by the recent WHO classification and appear to have great impact on the clinical course, but have not yet found their way into clinical risk stratification. Further, the overall unfavorable prognosis underlines the fact that current therapeutic strategies need further evaluation for improvement. To date, there is no international consensus regarding first-line treatment for children with intracranial EPN. Extent of resection is known to be the most important clinical risk factor, leading to the consensus that consequent evaluation for re-surgery of postoperative residual tumor needs to have highest priority. Furthermore, efficacy of local irradiation is unquestioned and recommended for patients aged>1 year. In contrast, efficacy of chemotherapy is still under discussion. The European trial SIOP Ependymoma II aims at evaluating efficacy of different chemotherapy elements, leading to the recommendation to include German patients. The BIOMECA study, as biological accompanying study, aims at identifying new prognostic parameters. These results might help to develop targeted therapies for unfavorable biological subtypes. For patient who are not qualified for inclusion into the interventional strata, the HIT-MED Guidance 5.2 provides specific recommendations. This article is meant as an overview of national guidelines regarding diagnostics and treatment as well as of treatment according to the SIOP Ependymoma II trial protocol. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 2 | |a Child |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Brain Neoplasms: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Brain Neoplasms: pathology |2 MeSH |
| 650 | _ | 2 | |a Prognosis |2 MeSH |
| 650 | _ | 2 | |a Combined Modality Therapy |2 MeSH |
| 650 | _ | 2 | |a Risk Factors |2 MeSH |
| 650 | _ | 2 | |a Ependymoma: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Ependymoma: therapy |2 MeSH |
| 650 | _ | 2 | |a Ependymoma: pathology |2 MeSH |
| 700 | 1 | _ | |a Mynarek, Martin |b 1 |
| 700 | 1 | _ | |a Stickan-Verfürth, Martina |b 2 |
| 700 | 1 | _ | |a Bison, Brigitte |b 3 |
| 700 | 1 | _ | |a Schüller, Ulrich |b 4 |
| 700 | 1 | _ | |a Pajtler, Kristian |0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |b 5 |u dkfz |
| 700 | 1 | _ | |a Hagel, Christian |b 6 |
| 700 | 1 | _ | |a Thomale, Ulrich-Wilhelm |b 7 |
| 700 | 1 | _ | |a Fleischhack, Gudrun |0 0000-0001-5714-007X |b 8 |
| 700 | 1 | _ | |a Timmermann, Beate |b 9 |
| 700 | 1 | _ | |a Rutkowski, Stefan |b 10 |
| 773 | _ | _ | |a 10.1055/a-2070-7572 |g Vol. 235, no. 3, p. 167 - 177 |0 PERI:(DE-600)2039110-9 |n 3 |p 167 - 177 |t Klinische Pädiatrie |v 235 |y 2023 |x 0300-8630 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:276077 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-22 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-08-28 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b KLIN PADIATR : 2022 |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-28 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-08-28 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::